Pulmonary sarcoidosis — staging & treatment
granulomatous · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Sarcoidosis is a multisystem granulomatous disease with frequent pulmonary and hilar nodal involvement. Many cases (especially Scadding stage I) remit spontaneously; treatment is reserved for progressive lung disease, major organ involvement or disabling symptoms.
Red flags
- Syncope, arrhythmia or heart block (cardiac sarcoid)
- New neurological deficit (neurosarcoidosis)
- Hypercalcaemia with renal impairment
- Progressive dyspnoea with falling DLCO (advancing fibrosis)
Assessment
Differential diagnosis
- Tuberculosis / NTM infection
- Lymphoma
- Berylliosis
- Hypersensitivity pneumonitis
- Fungal infection
- Metastatic malignancy / lymphangitis carcinomatosa
Investigations
- Chest X-ray for Scadding stage (I bilateral hilar nodes; II nodes+infiltrates; III infiltrates only; IV fibrosis)
- HRCT chest (perilymphatic nodularity, upper-zone fibrosis)
- Spirometry, lung volumes and DLCO
- Serum calcium, ACE, LFTs, renal function and FBC
- Tissue biopsy (EBUS-TBNA of nodes) showing non-caseating granulomas, with exclusion of infection
- ECG and consider cardiac MRI/PET if cardiac involvement suspected; ophthalmology review
Management
- Establish the diagnosis with compatible imaging plus non-caseating granulomas and exclusion of mimics
- Assess extent and organ involvement (lungs, heart, eyes, skin, liver, neuro, calcium)
- Stage pulmonary disease and measure baseline lung function and symptoms
- Identify high-risk involvement (cardiac, neuro, ocular, hypercalcaemia, renal) requiring treatment regardless of lung stage
- Observe asymptomatic stage I-II disease with normal/stable physiology — many remit
- Start oral corticosteroids for progressive/symptomatic pulmonary disease or major-organ disease
- Add a steroid-sparing agent (e.g. methotrexate) for relapse or steroid dependence
- Consider anti-TNF (infliximab) for refractory or neuro/cardiac disease
- Monitor lung function, symptoms, calcium and steroid toxicity on a planned schedule
- Treat fibrotic (stage IV) disease supportively; consider antifibrotics for progressive fibrosis and transplant for end-stage
Drugs & doses
Prednisolone 20-40 mg PO once daily, then slow taper to 5-10 mg maintenance over months
Methotrexate 10-15 mg PO once weekly with folic acid 5 mg weekly
Azathioprine 1-2 mg/kg PO once daily as alternative steroid-sparing agent
Infliximab 3-5 mg/kg IV at 0, 2, 6 weeks then every 4-8 weeks for refractory disease
Hydroxychloroquine 200-400 mg PO daily for cutaneous disease/hypercalcaemia
Disposition
Respiratory clinic; multidisciplinary input for cardiac/neuro/ocular involvement; transplant assessment for end-stage fibrosis.
Complications & pitfalls
- Pulmonary fibrosis and respiratory failure
- Pulmonary hypertension
- Cardiac arrhythmia / sudden death
- Hypercalcaemia and nephrolithiasis
- Steroid and immunosuppressant toxicity
Exam pearls
- Lofgren syndrome (erythema nodosum, bilateral hilar nodes, arthralgia) has an excellent prognosis and rarely needs steroids
- Serum ACE is neither sensitive nor specific — do not use it to diagnose or monitor
- Hypercalcaemia arises from macrophage 1-alpha-hydroxylase activity — advise sun/vitamin-D caution
- Cardiac and neuro involvement warrant treatment even with minimal lung disease
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.